On the 29th, the nurses brought Dad the traditional birthday cake, complete with serenade, to celebrate the re-birth of his immune system.
Go cells, go!
Subscribe to:
Post Comments (Atom)
skip to main |
skip to sidebar
Commentary from an Initial Participant in a Phase I/II Trial for the MCL Vaccine at Stanford University
Family Circa 1988
About Me
Technical Stuff
Many oncologists consider cancer vaccines to hold long-term promise but short term limitations. As with many of the newly developing treatment approaches, it is difficult to assess their effectiveness in the short term because study groups are often limited in size, and because it takes several years to determine their success as evidenced by the length of remission.
We have been impressed with Stanford's program for several reasons:
They have experienced some very impressive early successes with this vaccine in the treatment of other cancers.
Risks (side effects) are few, based on their treatment history.
And because it is combined with one of the most "standard" forms of MCL treatment, I am not taking any risks by forgoing conventional options.
Here is a summary of the program:
This study will evaluate the safety and efficacy of treating newly diagnosed mantle cell lymphoma patients with an autologous, tumor-derived vaccine followed by re-infusion of vaccine-primed T cells combined with standard autologous hematopoietic stem cell transplant (AHCT). CpG-MCL vaccine is derived from each patient's own tumor, treated in vitro with the immunostimulatory CpG-enriched oligodeoxynucleotide - PF-3512676 - and irradiated. The overall treatment schema is that patients receive: induction chemotherapy, preliminary vaccinations, pheresis to harvest vaccine-primed T cells, myeloablative chemotherapy followed by autologous stem cell rescue (AHCT) along with re-infusion of vaccine-primed T-cells ('immunotransplant') and repeat vaccinations zero and three months post-transplant.
If anyone wishes to learn more about the trial, please visit their page on the clincal trials website:
http://clinicaltrials.gov/ct2/show/NCT00490529?term=mantle+cell+lymphoma+and+stanford&recr=Open&rank=1
We have been impressed with Stanford's program for several reasons:
They have experienced some very impressive early successes with this vaccine in the treatment of other cancers.
Risks (side effects) are few, based on their treatment history.
And because it is combined with one of the most "standard" forms of MCL treatment, I am not taking any risks by forgoing conventional options.
Here is a summary of the program:
This study will evaluate the safety and efficacy of treating newly diagnosed mantle cell lymphoma patients with an autologous, tumor-derived vaccine followed by re-infusion of vaccine-primed T cells combined with standard autologous hematopoietic stem cell transplant (AHCT). CpG-MCL vaccine is derived from each patient's own tumor, treated in vitro with the immunostimulatory CpG-enriched oligodeoxynucleotide - PF-3512676 - and irradiated. The overall treatment schema is that patients receive: induction chemotherapy, preliminary vaccinations, pheresis to harvest vaccine-primed T cells, myeloablative chemotherapy followed by autologous stem cell rescue (AHCT) along with re-infusion of vaccine-primed T-cells ('immunotransplant') and repeat vaccinations zero and three months post-transplant.
If anyone wishes to learn more about the trial, please visit their page on the clincal trials website:
http://clinicaltrials.gov/ct2/show/NCT00490529?term=mantle+cell+lymphoma+and+stanford&recr=Open&rank=1
No comments:
Post a Comment